Progress in epidermal growth factor receptor-tyrosine kinase inhibitors-associated interstitial lung disease
- VernacularTitle:表皮生长因子受体酪氨酸激酶抑制剂相关间质性肺病的研究进展
- Author:
Minglang GAO
1
;
Yu DENG
1
;
Kai LAI
1
;
Ning LI
1
;
Qing GENG
1
Author Information
1. Department of Thoracic Surgery, Renmin Hospital of Wuhan University, Wuhan, 430000, P. R. China
- Publication Type:Journal Article
- Keywords:
Epidermal growth factor receptor-tyrosine kinase inhibitors;
adverse events;
interstitial lung disease;
inflammation;
mechanism of action;
tumor necrosis factor;
review
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2023;30(10):1499-1506
- CountryChina
- Language:Chinese
-
Abstract:
The tyrosine kinase activity of epidermal growth factor receptor (EGFR) plays a key role in tumor cell proliferation, invasion, migration, and drug resistance. Studies have shown that non-small cell lung cancer patients with somatic driver gene EGFR mutations are sensitive to and can benefit from EGFR-tyrosine kinase inhibitors (EGFR-TKIs). Nevertheless, EGFR-TKIs-related adverse events should not be ignored. Common adverse events such as diarrhea, acne-like rash and paronychia are usually manageable; although the incidence of interstitial lung disease is low, once it occurs, it is a serious threat to patients' life, and its pathogenesis is still unclear. There is very limited animal experimental and clinical research evidence on the potential mechanism of EGFR-TKIs-related interstitial lung disease in the available literature. Based on this, this article reviews the association between EGFR-TKIs and interstitial lung disease, at the same time, also discusses the research progress of EGFR-TKIs-related interstitial lung disease in combination with cytotoxic drugs or immunotherapeutic drugs and EGFR-TKIs, in order to provide a reference for the prevention and treatment of EGFR-TKIs-related interstitial lung disease in clinical practice in the future.
